SEC Form 4 · accession 0001179110-15-009170
ALBANY MOLECULAR RESEARCH INC · AMRI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven R Hagen
Officer — SVP Manufacturing & Pharmaceut
Period of report
Jun 2, 2015
Accepted (ET)
Jun 4, 2015 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001065087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2015 | F | 463 | $0.00 | D | 30,737 | D | |
| Common Stock | Jun 2, 2015 | D | 1,250 | $0.00 | D | 29,487 | D | |
| Common Stock | Jun 2, 2015 | M | 3,750 | $5.25 | A | 33,237 | D | |
| Common Stock | Jun 2, 2015 | S | 3,750 | $19.39 | D | 29,487 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF3 | $5.25 | Jun 2, 2015 | M | 3,750 | A | — | Jun 2, 2021 | Common Stock | 3,750 | 0 | D |
Explanation of responses
- F1Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person.
- F2Consists of shares forfeited due to performance conditions having not been met.
- F3Option grant was fully exercisable June 2, 2015.